Comparison of the Effect of Intralipid Parenteral Nutritional With SMOF Lipid Parenteral Nutritional on Biochemical Markers, Hematologic Markers, and Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study. Primary hypothesis is Patients receiving SMOF LIPID will have better grafts than patients receiving intralipid. Also, complications after surgery and malnutrition will be less in this group.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 18
Healthy Volunteers: f
View:

• Willingness to cooperate and complete the informed consent form by the legal guardian of the child;

• Age ≤ 18 years;

• Definitive diagnosis of acute leukemia and candidate for hematopoietic stem ● cell transplantation;

• Eligible for parenteral nutrition support;

• No contraindications for parenteral nutrition;

• No history of allergy to egg or soy protein;

• Absence of severe organ failure or impaired liver function test (bilirubin \> 2.5 mg/dL).

Locations
Other Locations
Islamic Republic of Iran
Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
RECRUITING
Tehran
Contact Information
Primary
Zahra Vahdat Shariatpanahi, Professor
nutritiondata@yahoo.com
0098-021-22357484
Backup
Zahra Vahdat Shariatpanahi, Professor
nutritiondata@yahoo.com
09122138186
Time Frame
Start Date: 2024-10-12
Estimated Completion Date: 2025-12
Participants
Target number of participants: 50
Treatments
Experimental: SMOF lipid
The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
Active_comparator: Intralipid
intralipids
Sponsors
Leads: Shahid Beheshti University

This content was sourced from clinicaltrials.gov